Before taking Lynparza(Olaparib)

Lynparza carries warnings for hematological, pulmonary, hepatic, and fetal risks.

Safety Considerations

Patients should be monitored for signs of MDS/AML, pneumonitis, liver injury, and blood clots. It is contraindicated in pregnancy due to fetal harm. Effective contraception is required for both female and male patients during and after treatment. Avoid concurrent use with strong CYP3A inducers or inhibitors.